Skip to content

Accidental coadministration of medetomidine, vatinoxan and ketamine in a cat.

Maria Koura, Eleni Koliou, Stavroula Kourmpeti, Georgios Kazakos

Veterinary anaesthesia and analgesia 2025 DOI: 10.1016/j.vaa.2025.03.011 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population 8-month-old Domestic Shorthair male cat
Interventions Medetomidine tramadol ketamine midazolam
Dose medetomidine 30 μg kg-1, tramadol 2 mg kg-1, ketamine 8 mg kg-1, midazolam 0.2 mg kg-1
Topics Ketamine Esketamine
Keywords Excitement Medetomidine Tachycardia Vatinoxan Veterinary medicine Drug interactions Anesthesia complications Feline surgery Medication safety
Citations 1
Key findings Accidental administration of medetomidine-vatinoxan instead of medetomidine alone, combined with ketamine, led to tachycardia and excitement in a cat undergoing elective orchiectomy.

Abstract

An 8-month-old, Domestic Shorthair male cat was presented for elective orchiectomy. Preanaesthetic clinical examination was unremarkable. The anaesthetic plan included intramuscular medetomidine (30 μg kg-1) and tramadol (2 mg kg-1) for premedication followed by intramuscular ketamine (8 mg kg-1) for induction of general anaesthesia. The premedication mixture, presumed to be medetomidine and tramadol, was given as a single injection. Approximately 15 minutes after premedication, the cat was profoundly sedated, with a heart rate of 140 beats minute-1. A catheter was placed in a cephalic vein. Ketamine was injected intramuscularly approximately 30 minutes after premedication in line with educational objectives. Within 2 minutes of injecting ketamine, the cat was exhibiting signs of excitement (mydriasis, head tilting, ataxia) and was no longer recumbent or cooperative, and its heart rate had increased to 280 beats minute-1. Examination of the drug vials used revealed that a combined formulation of medetomidine and vatinoxan had been inadvertently given, instead of medetomidine alone, as intended. Midazolam (0.2 mg kg-1) was given intravenously to counteract agitation. Surgery was postponed and the cat fully recovered (normal response to external stimuli, normal gait) approximately 1 hour after midazolam had been given. The predisposing factors contributing to this medication error were probably multifactorial: trainee involvement in anaesthesia care, similar appearance of drug vials and inadequate supervision during drug preparation. The medication error could explain the adverse events of tachycardia and excitement. Tachycardia may have been secondary to the effects of vatinoxan (offsetting bradycardia caused by the alpha-2 adrenergic receptor agonist) and ketamine (increasing heart rate), and the excitement resulting from the decreased plasma concentration of medetomidine (inadequate to counteract ketamine effects) when it is combined with vatinoxan. Given the inherent limitations of a single case observation, the ability to conclusively determine causes of the observed adverse events are limited.

Comparable studies

Other case reports and case series on ketamine, most cited first.

Study Year Design Participants
The destruction of the lower urinary tract by ketamine abuse: a new syndrome? Young recreational abusers of street-ketamine in Hong Kong referred to urology units 2008 Retrospective case series n = 59
Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. A patient with treatment-resistant depression and comorbid generalized anxiety... 2025 Case report n = 1
Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions Chronic and treatment-resistant eating disorder patients 1998 Case series n = 15
Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series Four depressed patients taking standard antidepressants 2009 Case series n = 4
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression Patients with enduring eating disorders and treatment-resistant depression 2021 Case series n = 4

Explore topics